|
1
|
Bishop MW, Janeway KA and Gorlick R:
Future directions in the treatment of osteosarcoma. Curr Opin
Pediatr. 28:26–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferrari S and Serra M: An update on
chemotherapy for osteosarcoma. Expert Opin Pharmacother.
16:2727–2736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xiang F, Ni Z, Zhan Y, Kong Q, Xu J, Jiang
J, Wu R and Kang X: Increased expression of MyD88 and association
with paclitaxel resistance in breast cancer. Tumour Biol.
37:6017–6025. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhu Y, Huang JM, Zhang GN, Zha X and Deng
BF: Prognostic significance of MyD88 expression by human epithelial
ovarian carcinoma cells. J Transl Med. 10:772012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liang B, Chen R, Wang T, Cao L, Liu Y, Yin
F, Zhu M, Fan X, Liang Y, Zhang L, et al: Myeloid differentiation
factor 88 promotes growth and metastasis of human hepatocellular
carcinoma. Clin Cancer Res. 19:2905–2916. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Salcedo R, Worschech A, Cardone M, Jones
Y, Gyulai Z, Dai RM, Wang E, Ma W, Haines D, O'Huigin C, et al:
MyD88-mediated signaling prevents development of adenocarcinomas of
the colon: Role of interleukin 18. J Exp Med. 207:1625–1636. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuo AH and Scheeren FA: Cell-intrinsic
TLR2/MyD88 pathway in breast and colon cancer. Cell Cycle.
13:3785–3786. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Di Padova F, Quesniaux VFJ and Ryffel B:
MyD88 as a therapeutic target for inflammatory lung diseases.
Expert Opin Ther Targets. 22:401–408. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang QL, Xie XB, Wang J, Chen Q, Han AJ,
Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, et al: Glycogen synthase
kinase-3β, NF-κB signaling, and tumorigenesis of human
osteosarcoma. J Natl Cancer Inst. 104:749–763. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu HY, Fang W, Huang ZW, Lu JC, Wang YQ,
Tang QL, Song GH, Kang Y, Zhu XJ, Zou CY, et al: Metformin reduces
SATB2-mediated osteosarcoma stem cell-like phenotype and tumor
growth via inhibition of N-cadherin/NF-kB signaling. Eur Rev Med
Pharmacol Sci. 21:4516–4528. 2017.PubMed/NCBI
|
|
11
|
Lu Y, Li F, Xu T and Sun J: Tetrandrine
prevents multidrug resistance in the osteosarcoma cell line, U-2OS,
by preventing Pgp overexpression through the inhibition of NF-κB
signaling. Int J Mol Med. 39:993–1000. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Loiarro M, Capolunghi F, Fantò N, Gallo G,
Campo S, Arseni B, Carsetti R, Carminati P, De Santis R, Ruggiero V
and Sette C: Pivotal Advance: Inhibition of MyD88 dimerization and
recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound.
J Leukoc Biol. 82:801–810. 2017. View Article : Google Scholar
|
|
13
|
Zhang Y, Meng W and Cui H: LncRNA CBR3-AS1
predicts unfavorable prognosis and promotes tumorigenesis in
osteosarcoma. Biomed Pharmacother. 102:169–174. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou Y, Zhang W, Tang F, Luo Y, Min L,
Zhang W, Shi R, Duan H and Tu C: A case report of apatinib in
treating osteosarcoma with pulmonary metastases. Medicine
(Baltimore). 96:e65782017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen X, Zhao F, Zhang H, Zhu Y, Wu K and
Tan G: Significance of TLR4/MyD88 expression in breast cancer. Int
J Clin Exp Pathol. 8:7034–7039. 2015.PubMed/NCBI
|
|
16
|
Kfoury A, Virard F, Renno T and Coste I:
Dual function of MyD88 in inflammation and oncogenesis:
Implications for therapeutic intervention. Curr Opin Oncol.
26:86–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng Y, Sun J and Zhang LD: Effect of
ST2825 on the proliferation and apoptosis of human hepatocellular
carcinoma cells. Genet Mol Res. 15:150168262016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shiratori E, Itoh M and Tohda S: MYD88
inhibitor ST2825 suppresses the growth of lymphoma and leukaemia
cells. Anticancer Res. 37:6203–6209. 2017.PubMed/NCBI
|
|
19
|
Warner N and Núñez G: MyD88: A critical
adaptor protein in innate immunity signal transduction. J Immunol.
190:3–4. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cervantes JL: MyD88 in Mycobacterium
tuberculosis infection. Med Microbiol Immunol. 206:187–193. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deguine J and Barton GM: MyD88: A central
player in innate immune signaling. F1000Prime Rep. 6:972014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chandhanayingyong C, Kim Y, Staples JR,
Hahn C and Lee FY: MAPK/ERK signaling in osteosarcomas, ewing
sarcomas and chondrosarcomas: Therapeutic implications and future
directions. Sarcoma. 2012:4048102012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meng Q, Zheng M, Liu H, Song C, Zhang W,
Yan J, Qin L and Liu X: TRAF6 regulates proliferation, apoptosis,
and invasion of osteosarcoma cell. Mol Cell Biochem. 371:177–186.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miwa S, Sugimoto N, Yamamoto N, Shirai T,
Nishida H, Hayashi K, Kimura H, Takeuchi A, Igarashi K, Yachie A
and Tsuchiya H: Caffeine induces apoptosis of osteosarcoma cells by
inhibiting AKT/mTOR/S6K, NF-κB and MAPK pathways. Anticancer Res.
32:3643–3649. 2012.PubMed/NCBI
|
|
25
|
Zhao Z, Wu MS, Zou C, Tang Q, Lu J, Liu D,
Wu Y, Yin J, Xie X, Shen J, et al: Downregulation of MCT1 inhibits
tumor growth, metastasis and enhances chemotherapeutic efficacy in
osteosarcoma through regulation of the NF-κB pathway. Cancer Lett.
342:150–158. 2014. View Article : Google Scholar : PubMed/NCBI
|
